Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04474314 · ClinicalTrials.gov registry record · Phase 2
A Study of IMR-687 in Subjects With Sickle Cell Disease
A Phase 2 study, sponsored by Cardurion Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 115
- Enrollment target
NCT04474314 is a Phase 2 study that was terminated before completion, run by Cardurion Pharmaceuticals. The registered enrollment target is 115 participants.
The verdict
NCT04474314, a Phase 2 study, was terminated before completion, sponsored by Cardurion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 115 participants
- Enrollment target
Study Summary
A Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease
Interventions
- DRUG Placebo
- DRUG IMR-687
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2020-08-13 |
| Est. Completion | 2022-05-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04474314
The ClinicalTrials.gov registry entry for NCT04474314 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cardurion Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04474314 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04474314 about?
NCT04474314 is a clinical study titled "A Study of IMR-687 in Subjects With Sickle Cell Disease". A Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease
What is the current status of trial NCT04474314?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 115 participants. The study started on 2020-08-13. Estimated completion is 2022-05-04.
What interventions are being tested in trial NCT04474314?
The interventions under investigation include: Placebo (DRUG), IMR-687 (DRUG).
Who is sponsoring clinical trial NCT04474314?
This trial is sponsored by Cardurion Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.